Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA)

Last updated: April 20, 2012
Sponsor: Sanofi
Overall Status: Completed

Phase

3

Condition

Coronary Artery Disease

Hypercholesterolemia

Atherosclerosis

Treatment

N/A

Clinical Study ID

NCT00050817
EFC4505
  • Ages > 45
  • All Genders

Study Summary

RATIONALE:

  • Atherothrombosis is a progressive and generalized vascular disease resulting in events leading to myocardial infarction (heart attack), stroke, and vascular death.

  • In patients at risk for this disease, it is characterized by an unpredictable, sudden disruption of atherosclerotic plaques, which may lead to total occlusion of artery due to formation of a clot. The use of aspirin (blood thinner agent) for reducing those major ischemic events is either indicated, or recommended by international guidelines. However, aspirin fails to prevent a high percentage of such life-threatening events. Therefore, more effective blood thinning therapy may provide additional clinical benefit to such patients.

  • The results of the CURE trial in patients with unstable angina demonstrate the additional benefit of long-term treatment (up to one year) with clopidogrel, (a blood thinner agent), when administered in combination with standard therapy including aspirin. The purpose of CHARISMA is to investigate whether a similar clinical benefit of clopidogrel may apply to a broad population of high-risk patients receiving low-dose aspirin therapy. Such population includes patients with previous cardiovascular, neurovascular or peripheral arterial manifestations of atherothrombosis and patients with combinations of recognized risk factors for atherosclerosis.

OBJECTIVES:

  • To assess the efficacy of clopidogrel 75 mg once-daily by comparison with a placebo, in preventing cardiovascular morbidity/mortality. The study will compare the efficacy of the two regimens in preventing the occurrence of major cardiovascular complications (stroke, heart attack, cardiovascular death) in high-risk patients who are otherwise receiving low-dose aspirin therapy (75-162 mg daily).

  • To evaluate the safety of clopidogrel in this population, and more specifically the incidence of fatal or severe bleeding (as per GUSTO definition), in order to estimate the global benefit of clopidogrel in this patient population.

Eligibility Criteria

Inclusion

INCLUSION:

Be at least 45 years old and comply with at least one of the four categories of inclusion criteria:

  • Combination of atherothrombotic risk factors (2 major or 3 minor or 1 major + 2 minor risk factors among those listed below)

Major atherothrombotic risk factors

  • Type I or II diabetes (under drug therapy)

  • Diabetic nephropathy

  • Ankle brachial index (ABI) < 0.9

  • Asymptomatic carotid stenosis >= 70%

  • At least one carotid plaque as evidenced by intima-media thickness (IMT)

Minor atherothrombotic risk factors

  • Systolic blood pressure (SBP) >= 150 mmHg, despite appropriate therapy for at least 3 months

  • Primary hypercholesterolemia

  • Current smoking > 15 cigarettes per day

  • Male >= 65 years

  • Female >= 70 years

and/or

  • Documented cerebrovascular disease (TIA or IS within 5 years) and/or

  • Documented coronary artery disease (stable angina with documented multivessel coronary disease, previous documented MI, multivessel PCI or CABG within 1 year, multivessel CABG older than 1 year associated with current angina) and/or

  • Documented symptomatic PAD

EXCLUSION:

  • Absolute indication for the use of clopidogrel, high-dose aspirin (>162 mg), NSAIDs, or oral anti-thrombotic drugs

  • Absolute contraindication to the use of clopidogrel or aspirin

  • Clinical conditions likely to interfere with follow-up leading to inability to complete the trial

Study Design

Total Participants: 15603
Study Start date:
October 01, 2002
Estimated Completion Date:
August 31, 2005

Study Description

TREATMENTS:

  • Clopidogrel (Plavix® and/or Iscover®) is an agent inhibiting platelet aggregation involved in clot formation. Each tablet contains 75mg of clopidogrel. A matching placebo of clopidogrel is an inactive substance that looks similar to the active clopidogrel tablet.

TREATMENT PLAN:

  • There will be two treatment groups; one will receive clopidogrel 75 mg (1 tablet qd), the second matching placebo of clopidogrel (1 tablet qd). These study drugs will be administered on top of low-dose aspirin (75-162 mg qd) systematically prescribed to such patients. In addition, patients enrolled in CHARISMA will be managed as appropriate for their risk factors for atherosclerosis: eg. high blood pressure, high cholesterol, diabetes…etc.

PRIMARY ENDPOINT:

  • Combined endpoint of cardiovascular mortality, stroke, acute myocardial infarction.

STUDY EXECUTION:

  • Some 7,600 patients per group will be recruited within two years. Patients will be observed over a maximum of 3.5 years.

STUDY TERRITORY:

  • Approximately 900 sites throughout North/South America, Europe, Asia, Australia, and South Africa.

Connect with a study center

  • Sanofi-aventis Administrative Office

    Buenos Aires,
    Argentina

    Site Not Available

  • Sanofi-aventis Administrative Office

    Macquarie Park,
    Australia

    Site Not Available

  • Sanofi-aventis Administrative Office

    Wien,
    Austria

    Site Not Available

  • Sanofi-aventis Administrative Office

    Diegem,
    Belgium

    Site Not Available

  • Sanofi-aventis Administrative Office

    Sao Paulo,
    Brazil

    Site Not Available

  • Sanofi-aventis Administrative Office

    Laval,
    Canada

    Site Not Available

  • Sanofi-aventis Administrative Office

    Santiago,
    Chile

    Site Not Available

  • Sanofi-aventis Administrative Office

    Praha,
    Czech Republic

    Site Not Available

  • Sanofi-aventis Administrative Office

    Horsholm,
    Denmark

    Site Not Available

  • Sanofi-aventis Administrative Office

    Helsinki,
    Finland

    Site Not Available

  • Sanofi-aventis Administrative Office

    Paris,
    France

    Site Not Available

  • Sanofi-aventis Administrative Office

    Berlin,
    Germany

    Site Not Available

  • Sanofi-aventis Administrative Office

    Athens,
    Greece

    Site Not Available

  • Sanofi-aventis Administrative Office

    Causeway Bay,
    Hong Kong

    Site Not Available

  • Sanofi-aventis Administrative Office

    Budapest,
    Hungary

    Site Not Available

  • Sanofi-aventis Administrative Office

    Milano,
    Italy

    Site Not Available

  • Sanofi-aventis Administrative Office

    Kuala Lumpur,
    Malaysia

    Site Not Available

  • Sanofi-aventis Administrative Office

    Mexico,
    Mexico

    Site Not Available

  • Sanofi-aventis Administrative Office

    Gouda,
    Netherlands

    Site Not Available

  • Sanofi-aventis Administrative Office

    Lysaker,
    Norway

    Site Not Available

  • Sanofi-aventis Administrative Office

    Warszawa,
    Poland

    Site Not Available

  • Sanofi-aventis Administrative Office

    Porto Salvo,
    Portugal

    Site Not Available

  • Sanofi-aventis Administrative Office

    Moscow,
    Russian Federation

    Site Not Available

  • Sanofi-aventis Administrative Office

    Singapore,
    Singapore

    Site Not Available

  • Sanofi-aventis Administrative Office

    Midrand,
    South Africa

    Site Not Available

  • Sanofi-aventis Administrative Office

    Barcelona,
    Spain

    Site Not Available

  • Sanofi-aventis Administrative Office

    Bromma,
    Sweden

    Site Not Available

  • Sanofi-aventis Administrative Office

    Geneva,
    Switzerland

    Site Not Available

  • Sanofi-aventis Administrative Office

    Taipei,
    Taiwan

    Site Not Available

  • Sanofi-aventis Administrative Office

    Istanbul,
    Turkey

    Site Not Available

  • Sanofi-aventis Administrative Office

    Guildford Surrey,
    United Kingdom

    Site Not Available

  • The Cleveland Clinic Foundation

    Cleveland, Ohio 44195
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.